This company listing is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
PAVmed 관리
관리 기준 확인 2/4
PAVmed's CEO is Lishan Aklog, appointed in Jun 2014, has a tenure of 9.75 years. total yearly compensation is $1.45M, comprised of 62.1% salary and 37.9% bonuses, including company stock and options. directly owns 4.67% of the company’s shares, worth €950.27K. The average tenure of the management team and the board of directors is 1.5 years and 9.2 years respectively.
주요 정보
Lishan Aklog
최고 경영자
US$1.5m
총 보상
| CEO 급여 비율 | 62.1% |
| CEO 임기 | 9.8yrs |
| CEO 소유권 | 4.7% |
| 경영진 평균 재임 기간 | 1.5yrs |
| 이사회 평균 재임 기간 | 9.2yrs |
최근 관리 업데이트
Recent updates
CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$79m |
| Mar 31 2023 | n/a | n/a | -US$90m |
| Dec 31 2022 | US$1m | US$901k | -US$89m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$72m |
| Mar 31 2022 | n/a | n/a | -US$58m |
| Dec 31 2021 | US$9m | US$583k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$42m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$1m | US$431k | -US$35m |
| Sep 30 2020 | n/a | n/a | -US$32m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$890k | US$431k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$772k | US$346k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$12m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$10m |
| Dec 31 2017 | US$444k | US$297k | -US$10m |
보상 대 시장: Lishan's total compensation ($USD1.45M) is above average for companies of similar size in the German market ($USD411.63K).
보상과 수익: Lishan's compensation has been consistent with company performance over the past year.
CEO
Lishan Aklog (57 yo)
9.8yrs
테뉴어
US$1,450,291
보상
Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & CEO | 9.8yrs | US$1.45m | 4.67% $ 950.3k | |
| President | 7yrs | US$1.11m | 0.63% $ 128.5k | |
| Executive VP & COO | 2.1yrs | US$1.44m | 0.22% $ 45.3k | |
| Executive VP | less than a year | US$593.10k | 0.056% $ 11.5k | |
| Senior VP of Molecular Genetics & Chief Scientific Officer | 1.2yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP | 1.8yrs | 데이터 없음 | 0% $ 0 | |
| Senior VP | 1.2yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Medical Officer | 1.2yrs | 데이터 없음 | 데이터 없음 |
1.5yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 관리: 1P50's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & CEO | 9.8yrs | US$1.45m | 4.67% $ 950.3k | |
| Independent Director | 9.2yrs | US$182.23k | 0.81% $ 164.4k | |
| Member of Medical Advisory Board | 9.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2.8yrs | US$173.60k | 0.81% $ 164.4k | |
| Independent Director | 9.2yrs | US$163.60k | 0.81% $ 164.4k | |
| Member of Medical Advisory Board | 9.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 | |
| Independent Vice Chairman | 9.4yrs | US$163.60k | 3.91% $ 796.5k | |
| Member of Medical Advisory Board | 9.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2.9yrs | US$183.60k | 0.81% $ 164.4k | |
| Member of Medical Advisory Board | 7.3yrs | 데이터 없음 | 데이터 없음 |
9.2yrs
평균 재임 기간
60.5yo
평균 연령
경험이 풍부한 이사회: 1P50's board of directors are considered experienced (9.2 years average tenure).